Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy~* Has normal organ function; is no greater than 2 on the ECOG Performance Scale~* Has a negative blood or urine pregnancy test within 72 hours of receiving the first dose of study drug if participant is female~* Is able to swallow capsules and has no surgical or bodily condition that will prevent the patient from swallowing and absorbing oral medications on an ongoing basis~Exclusion Criteria:~* Participant has had chemotherapy, radiotherapy, biological therapy or surgery within 4 weeks of starting the study and has not recovered from adverse events caused by the treatment~* Is currently participating or has participated in a study with an investigational compound or device within 30 days~* Has a primary central nervous system tumor~* Has a history or current evidence of heart disease, slow heart rate or untreated high blood pressure~* Is a known diabetic who is taking insulin or oral antidiabetic therapy~* Is pregnant or breastfeeding or planning to become pregnant during the study~* Is HIV-positive~* Has known history of Hepatitis B or C or active Hepatitis A~* Is receiving treatment with oral corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-2206 30 mg QOD (Type: EXPERIMENTAL): Participants receive 30 mg oral MK-2206 every other day (QOD) in repeating 4-week treatment cycles.
- MK-2206 60 mg QOD (Type: EXPERIMENTAL): Participants receive 60 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
- MK-2206 75 mg QOD (Type: EXPERIMENTAL): Participants receive 75 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
- MK-2206 90 mg QOD (Type: EXPERIMENTAL): Participants receive 90 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
- MK-2206 90 mg QW (Type: EXPERIMENTAL): Participants receive 90 mg oral MK-2206 every week (QW) in repeating 4-week treatment cycles.
- MK-2206 135 mg QW (Type: EXPERIMENTAL): Participants receive 135 mg oral MK-2206 QW in repeating 4-week treatment cycles.
- MK-2206 200 mg QW (Type: EXPERIMENTAL): Participants receive 200 mg oral MK-2206 QW in repeating 4-week treatment cycles.
- MK-2206 300 mg QW (Type: EXPERIMENTAL): Participants receive 300 mg oral MK-2206 QW in repeating 4-week treatment cycles.
- MK-2206 250 mg QW (Type: EXPERIMENTAL): Participants receive 250 mg oral MK-2206 QW in repeating 4-week treatment cycles.
- MK-2206 150 mg QW (Type: EXPERIMENTAL): Participants receive 150 mg oral MK-2206 QW in repeating 4-week treatment cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete